GlaxoSmithKline plc (GSK) Shares Bought by Buckhead Capital Management LLC
Buckhead Capital Management LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 41.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,200 shares of the pharmaceutical company’s stock after purchasing an additional 7,390 shares during the period. Buckhead Capital Management LLC’s holdings in GlaxoSmithKline were worth $894,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Canandaigua National Bank & Trust Co. lifted its position in shares of GlaxoSmithKline by 14.6% during the 4th quarter. Canandaigua National Bank & Trust Co. now owns 15,297 shares of the pharmaceutical company’s stock valued at $543,000 after buying an additional 1,950 shares during the last quarter. Calton & Associates Inc. purchased a new position in shares of GlaxoSmithKline during the 4th quarter valued at $300,000. Zevin Asset Management LLC lifted its position in shares of GlaxoSmithKline by 24.0% during the 4th quarter. Zevin Asset Management LLC now owns 68,506 shares of the pharmaceutical company’s stock valued at $2,430,000 after buying an additional 13,250 shares during the last quarter. Claraphi Advisory Network LLC purchased a new position in shares of GlaxoSmithKline during the 4th quarter valued at $264,000. Finally, SeaCrest Wealth Management LLC purchased a new position in shares of GlaxoSmithKline during the 4th quarter valued at $402,000. 9.66% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on GSK shares. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Argus dropped their price target on GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a research report on Thursday, November 30th. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their price target for the company from $35.04 to $35.85 in a research report on Monday, November 27th. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Wednesday, October 18th. Finally, ValuEngine cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $38.57.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.03. The business had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. analysts expect that GlaxoSmithKline plc will post 2.96 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Shares Bought by Buckhead Capital Management LLC” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/02/09/glaxosmithkline-plc-gsk-shares-bought-by-buckhead-capital-management-llc.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.